MEDIOS

Medios Group: Revision of Guidance 2026

Thomas Meier, CEO

Stefan Bauerreis, CFO

July 29, 2026

Revision of Guidance 2026

Medios Group: Expected Development of Revenues in 2026

External Revenue (H1 2026)
in m€

+€83.2m
+8.4% (YoY)



Revenue growth in all operational segments stable with slightly lower growth rates in Segment International Business compared to the other segments

Revision of Guidance 2026

Medios Group: Expected EBITDA pre Development in 2026

Pharmaceutical Supply

- Price pressure on specific high-margin medicines in the market to continue in H2 2026
- Implication of new law (GKV-Beitragssatzstabilisierungsgesetz) with negative impact on profitability with Cannabis Flowers due to stop of reimbursement
- Assumed implementation of new law: Immediately and therefore negative impact in H2 2026 revenues and margin expected.

International Business

- Last months with pressure on profitability in some specific business fields with negative impact on expected performance in H2 2026
- Improvements in implementation phase with positive impact expected in 2027

Patient-Specific Therapies

- Margin improvements expected due to implementation of cost optimizations (e.g. Medios Avanti)
- Closure of Aschaffenburg with delivery of all customers from other locations with positive impact on margin

Medios Group: Revision of Guidance 2026 as of July 29, 2026

Revenue
in b€



EBITDA pre
in m€



- Focus on **operational excellence** remains key
- **Growth in all segments** remains valid
- **Compounding** as main area of future development

Contact

Claudia Nickolaus
Head of Investor & Public Relations
Phone +49 30 232 566 800

Claudia.Nickolaus@medios.group

MEDIOS